Monday 7th November 2022
Government Must Act on Cost of Living to Protect Health of Millions With Raynaud's, Says SRUK
SRUK Survey highlights the devastating impact of the cost-of-living crisis and high energy bills for people with Raynaud's.
Friday 4th November 2022
RAIRDA Report - Resetting the Balance
The Rare Autoimmune Rheumatic Disease Alliance (RAIRDA) which SRUK is a member of, has released a report highlighting ‘alarming disparities in the quality of care and treatment’ received by people living with rare autoimmune rheumatic diseases (RAIRDs).
Monday 10th October 2022
Winter Vaccinations: Get Your COVID-19 Boosters & Flu Vaccines Now!
To help protect those at risk from COVID-19 & flu, the NHS is currently offering flu vaccines and an autumn COVID booster to those with weakened immune systems, the over 50s, and household members of those who are deemed clinically vulnerable. These vaccines can reduce your chances of catching the viruses and getting seriously ill as a result of them. It's as important as ever to make sure that you, and those in close contact to you, are protected from infection before winter rolls around, so read more about how to get both vaccines here!
Wednesday 5th October 2022
Reducing Uncertainty in the Progression of Lung Fibrosis in Scleroderma Patients
Having scleroderma often means living with uncertainty around how the disease will progress over time, and the effect that this could have on future quality of life. New research funded by SRUK aims to help address the impact of this ‘prognostic uncertainty’, by using indicators that will predict disease progression and ultimately improve treatment options.
Tuesday 20th September 2022
From cancer to autoimmunity: Could CAR T cell therapy cure scleroderma?
CAR T cells are an exciting and emerging therapy which have been used to treat certain cancers, giving hope to those for whom no other treatments have worked. A recent study carried out in Germany which studied patients with lupus suggests that this therapy could be of use in treating a host of autoimmune conditions including scleroderma.
Wednesday 14th September 2022
Oral and Dental Problems in Scleroderma: New SRUK-Funded Research Aims to Improve Pathways to Oral Care
Exciting new research run by Professor Liz Walker at the University of Hull and the University of Leeds is aiming to improve oral and dental outcomes for people living with scleroderma, by improving pathways to oral care. You can now get involved in the research team’s study by filling out their short survey about your perspectives on dental and oral care in scleroderma. Find the link on this page!
Friday 9th September 2022
Evusheld Survey: New treatment to prevent COVID-19 infection in people with poor immune systems
Do you have scleroderma and have a weakened immune system? Would you like to have your say on whether a treatment which can prevent COVID-19 infection is made available to those who have poor immune responses in response to COVID-19 vaccination? Complete our short survey to inform our response to a NICE consultation on whether this treatment should be authorised for use.
Wednesday 7th September 2022
Helping demystify multi-organ fibrosis: The DEMISTIFI study
Would you like to find out more about a new study that aims to improve how we understand and treat fibrosis?
Tuesday 9th August 2022
The Decode Scleroderma Study
72 people have signed up for this new trial for people living with diffuse scleroderma and now this clinical study, to test a new investigational drug for use in Diffuse Scleroderma, is ready to start.
Monday 1st August 2022
SRUK supports the call on the UK Government to provide Evusheld - a preventative antibody treatment for COVID-19
Evusheld is an antibody treatment designed to prevent patients from contracting COVID-19, and can provide protection for immunocompromised and immunosuppressed people that haven’t mounted a proper response to the vaccine. SRUK is supporting the call for the UK Government to procure and provide Evusheld to patients in the UK. Find out about how you can help on this page.